Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility . Bar graph shows the mean +/-SD of BW in A) control or STZ treated B6 or D2 mice and B) Akita B6 or D2 mice at baseline, 3, 6, 12 weeks of diabetes as indicated. FBG levels +/-SD of C) control or STZ treated B6 or D2 mice, and of D) Akita B6 or D2 mice at baseline, 3, 6, 12 weeks of diabetes. *P < 0.05, **P < 0.01, or # P < 0.001.
Supplementary Figure 2. Mitochondrial gene expression in diabetic B6 and D2 mice glomeruli
Total RNA was prepared from glomeruli and cell lysates (Qiagen, Valencia, CA) and reversely transcribed into single strand cDNA with SuperScript II reverse transcriptase(Life Technologies, Invitrogen). The cDNA was amplified using SYBR-Green PCR Master Mix (Applied Biosystems) and gene-specific exon-exon junction spanning primers (sequences available upon request), normalized the murine beta-actin gene or Gapdh. Relative mRNA expression levels of selected respiratory chain complex genes in STZ treated B6 and D2 mice with A) 3 weeks and B) 6 weeks of diabetes compared with respective non-diabetic controls. *P < 0.05, **P < 0.01.
Supplementary Figure 3. MitoTEMPO ameliorated glomerulosclerosis of STZ-D2 and Akita-D2 diabetic mice
A) FBG levels of control, STZ-D2 and STZ-D2 co-treated with mitoTEMPO with 3 weeks of diabetes. PAS staining of D2 kidneys B) STZ-D2 mice showing severe sclerosis, C) STZ-D2 co-treated with mitoTEMPO (1mg/kg/day). D) Sclerosis score of STZ-D2 with/without mitoTEMPO. PAS staining of E) Akita-D2 mice, F) Akita-D2 co-treated with mitoTEMPO (1mg/kg/day) and G) Sclerosis index score of Akita-D2 with/without mitoTEMPO. The Sclerosis index score in D) and E) was performed as previously described (1), for each glomerulus and graded from 0 to 4+ as follows: 0 represents no lesion, 1+ represents sclerosis of <25% of the glomerulus, while 2+, 3+, and 4+ represents sclerosis of >25% to 50%, >50% to 75%, and >75% of the glomerulus. + P< 0.05, **P < 0.01, ns not significant.
Supplementary Figure 4. BQ-123 does not affect STZ-D2 FBG
A) FBG levels of control, STZ-D2 and STZ-D2 co-treated with BQ-123 with 3 weeks of diabetes. **P < 0.01, ns not significant. Figure 6 . mitochondrial and endothelial function with hGluctreatment of mGECs A) baseline OCR, ATP linked OCR calculated as the difference between basal and oligomycin-sensitive OCR, and reserve capacity OCR of mGEC controls (glucose (5mM) + D-mannitol (25mM)), or treated with hGluc, or NOS inhibitor L-NAME. B) eNOS activity of mGEC controls in RPMI, or treated with hGluc, or NOS inhibitor L-NAME.
Supplementary

Supplementary Table 1.
Top ten differentially represented pathways in glomeruliaser 6 weeks of diabetes. # Down suggests reduced pathway activity, * Up suggests increased pathway activity
